


Oncolife

Glioma

COMPREHENSIVE

Comprehensive Panel With inclusion of (IHC, FISH & NGS) markers helpful in early detection of Glioma, its prognosis and treatment depending on the glioma type


Clinical Utility

- The Biomarker panel analyze the glioma for molecular changes in genes, proteins and other markers to establish the diagnosis.
 - The panel helps is required for final subtyping of Glioma and finalize suitable options for treatment.
 - Biomarker testing can improve the accuracy of the diagnosis and help narrow down options for treatment.
- 

AMC/ACMG/ASCO/CAP/NCCN/EMA/ESMO

Guidelines followed

1p19q codeletion (FISH) | MGMT (Methylation Pcr) | TP53 | PTEN | BRAF (NGS) | IDH1 & 2 (NGS) | EGFR amplification (FISH) | Ki67 (IHC) | ATRX mutation (IHC)



Test Details

Test Name	Test Components	Specimen	Method	TAT
Oncolife Glioma Comprehensive	*1p19q codeletion (FISH)*MGMT (Methylation Pcr) *TP53 *PTEN *BRAF (NGS) *IDH1 & 2 (NGS) *EGFR amplification(FISH) *Ki67 *ATRX mutation (IHC)	FFPE Tissue/Paraffin block Histopathology report must accompany the specimen	NGS, FISH, IHC	14 days
Oncolife - Glioma Panel Extended	*IDH1/IDH2(NGS)*MGMT *TP53 (IHC) *ATRX(IHC) *EGFR amplification			
Oncolife - Theranostic Glioma Panel	IDH1/IDH2(exon 4), codeletion 1p/19q, MGMT (3 genes)		NGS, FISH, Methylation PCR	14 days
FISH for 1p/19q Deletion (Oligodendrogliomas) Tissue	*1p19q codeletion (FISH)*		FISH	5 days
MGMT Promoter Methylation analysis	MGMT		Methylation PCR	15 days
IDH1/2 Mutation Analysis	IDH1/IDH2		NGS	10 days